BR112022016342A2 - Biciclos à base de pirimidina como agentes antivirais para o tratamento e prevenção da infecção por hiv - Google Patents

Biciclos à base de pirimidina como agentes antivirais para o tratamento e prevenção da infecção por hiv

Info

Publication number
BR112022016342A2
BR112022016342A2 BR112022016342A BR112022016342A BR112022016342A2 BR 112022016342 A2 BR112022016342 A2 BR 112022016342A2 BR 112022016342 A BR112022016342 A BR 112022016342A BR 112022016342 A BR112022016342 A BR 112022016342A BR 112022016342 A2 BR112022016342 A2 BR 112022016342A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
hiv
pyrimidine
antiviral agents
Prior art date
Application number
BR112022016342A
Other languages
English (en)
Inventor
Vitalievich Kurkin Alexander
Vladimirovna Manasova Ekaterina
Nikolaevich Kazyulkin Denis
Nikolaevich Ivanov Vladimir
Gennadievich Shurygin Mikhail
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020107455A external-priority patent/RU2780101C2/ru
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of BR112022016342A2 publication Critical patent/BR112022016342A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

BICICLOS À BASE DE PIRIMIDINA COMO AGENTES ANTIVIRAIS PARA O TRATAMENTO E PREVENÇÃO DA INFECÇÃO POR HIV. Esta invenção se refere a derivados de pirimidina, os quais tem inibição da replicação do HIV. A presente invenção fornece novos compostos de pirimidina, projetados para o tratamento e a prevenção de doenças mediadas pelo HIV. A invenção ainda se refere a composições farmacêuticas e fármacos contidos nas mesmas. A invenção também se refere ao uso dos compostos acima mencionados para o tratamento e / ou a prevenção do HIV em indivíduos com infecção pelo HIV (vírus da imunodeficiência humana) ou que tem risco de contrair a infecção pelo HIV.
BR112022016342A 2020-02-19 2021-02-18 Biciclos à base de pirimidina como agentes antivirais para o tratamento e prevenção da infecção por hiv BR112022016342A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020107455A RU2780101C2 (ru) 2020-02-19 Противовирусные средства для лечения и профилактики вич-инфекции
PCT/RU2021/000070 WO2021167495A1 (en) 2020-02-19 2021-02-18 Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of hiv infection

Publications (1)

Publication Number Publication Date
BR112022016342A2 true BR112022016342A2 (pt) 2022-10-04

Family

ID=71741532

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016342A BR112022016342A2 (pt) 2020-02-19 2021-02-18 Biciclos à base de pirimidina como agentes antivirais para o tratamento e prevenção da infecção por hiv

Country Status (15)

Country Link
US (1) US20230120294A1 (pt)
EP (1) EP4107156A1 (pt)
JP (1) JP2023515080A (pt)
KR (1) KR20220129043A (pt)
CN (1) CN115279757A (pt)
AU (2) AU2021224460A1 (pt)
BR (1) BR112022016342A2 (pt)
CA (1) CA3158698A1 (pt)
CO (1) CO2022013187A2 (pt)
CU (1) CU20220045A7 (pt)
IL (1) IL290285A (pt)
JO (1) JOP20220188A1 (pt)
PE (1) PE20230559A1 (pt)
WO (1) WO2021167495A1 (pt)
ZA (1) ZA202207489B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115028527A (zh) * 2022-05-28 2022-09-09 汉瑞药业(荆门)有限公司 一种3-羟甲基-2,2-二甲基环丙基甲酸的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4858877B2 (ja) 2004-09-28 2012-01-18 エスティー‐エリクソン、ソシエテ、アノニム 電流モード制御ｄｃ−ｄｃコンバータ
RU2405778C2 (ru) 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
WO2006035068A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
JP5118972B2 (ja) 2004-10-29 2013-01-16 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性二環式ピリミジン誘導体
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
SI1858861T1 (sl) 2005-03-04 2010-10-29 Tibotec Pharm Ltd 2-(4-cianofenil)-6-hidroksilaminopirimidini, ki inhibirajo HIV
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
WO2017090719A1 (ja) * 2015-11-27 2017-06-01 大鵬薬品工業株式会社 縮環ピリミジン化合物又はその塩
CN106117242B (zh) * 2016-06-27 2018-08-03 山东大学 四氢噻喃并嘧啶类衍生物及其制备方法与应用
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用

Also Published As

Publication number Publication date
WO2021167495A1 (en) 2021-08-26
CN115279757A (zh) 2022-11-01
JOP20220188A1 (ar) 2023-01-30
US20230120294A1 (en) 2023-04-20
JP2023515080A (ja) 2023-04-12
PE20230559A1 (es) 2023-03-31
RU2020107455A3 (pt) 2021-05-05
CA3158698A1 (en) 2021-08-26
IL290285A (en) 2022-04-01
EP4107156A1 (en) 2022-12-28
CU20220045A7 (es) 2023-03-07
KR20220129043A (ko) 2022-09-22
RU2020107455A (ru) 2020-07-27
AU2021224460A1 (en) 2022-12-15
CO2022013187A2 (es) 2022-09-20
ZA202207489B (en) 2023-03-29
AU2024200431A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112022018236A2 (pt) Compostos antivirais e métodos para a sua administração
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
BR112022016342A2 (pt) Biciclos à base de pirimidina como agentes antivirais para o tratamento e prevenção da infecção por hiv
BR112017000285A2 (pt) métodos de tratamento da profilaxia viral e kits de profilaxia de pré-exposição
Jiang et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis
López Galera et al. Interaction between cat’s claw and protease inhibitors atazanavir, ritonavir and saquinavir
de Matos et al. Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
Tremblay et al. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro
BR112023020893A2 (pt) Aptâmeros para uso no tratamento de infecções por coronaviridae
US9084758B2 (en) Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof
Adewale et al. Effects of a single pill 3-drug combination of lamivudine, nevirapine and zidovudine on blood parameters and liver histology in female wistar rats
BR112022021304A2 (pt) Métodos para profilaxia e tratamento de covid e covid-19.
Leung et al. Are face masks useful for limiting the spread of COVID-19?
Cavenaghi et al. Protease inhibitor and metabolic alteration
Mascolini HIV prevention fails in all three VOICE arms, as daily Truvada PrEP falls
Neves Optimal dosing & time: Issues to get hydroxychloroquine safety & efficacy against COVID-19/SARS-CoV-2
Mardani Could Molnupiravir Reduce Viral Burden of COVID-19?
BR112021021454A2 (pt) Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
Osonuga et al. Hematologic Toxicity of Antiretroviral Drug, Zidolam (zidovudine and lamivudine) in Adult Wistar Rats
BR102021016873A2 (pt) Uso do ambenônio para inibição de proteases de coronavírus, com aplicação no combate a coronaviroses
Nandy et al. Analysis of causation of Stevens Johnson Syndrome in a patient of rheumatoid arthritis with increased dose of methotrexate
Lambert HIV post-exposure prophylaxis following needle-stick injuries
Osonuga et al. Gonadotoxicity evaluation of oral administration of zidolam in male albino rats.